CoChat

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Open access
Bowlus, Christopher L., Galambos, Michael R., Aspinall, Richard J., Hirschfield, Gideon M., Jones, David E.J., Dörffel, Yvonne, Gordon, Stuart C., Harrison, Stephen A., Kremer, Andreas E., Mayo, Marlyn J., Thuluvath, Paul J., Levy, Cynthia, Swain, Mark G., Neff, Guy W., Sheridan, David A., Stanca, Carmen M., Berg, Christoph P., Goel, Aparna, Shiffman, Mitchell L., Vierling, John M., Boudes, Pol, Steinberg, Alexandra, Choi, Yun-Jung, McWherter, Charles A. · 2022 · Journal of Hepatology
Cited by 80

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary cholangitis (PBC) at risk of disease progression (alkaline phosphatase [ALP] ≥1.67xupper limit of normal [ULN]) who were receiving or intolerant to ursodeoxycholic acid. METHODS: In this 52-week, phase II, dose-ranging, open-label study, patients were randomized (1:1) to seladelpar 5 mg/day (n = 53) or 10 mg/day (n = 55) or assigned to 2 mg/day (n = 11; United Kingdom sites after interim analysis) for 12 weeks. Doses could then be uptitrated to 10 mg/day. The primary efficacy endpoint was ALP change from baseline to Week 8. RESULTS: Mean baseline ALP was 300, 345, and 295 U/L in the 2 mg, 5 mg, and 10 mg cohorts, respectively. Twenty-one percent of patients had cirrhosis, 71% had pruritus. At Week 8, mean ± standard error ALP reductions from baseline were 26 ± 2.8%, 33 ± 2.6%, and 41 ± 1.8% in the 2 mg (n = 11), 5 mg (n = 49), and 10 mg (n = 52) cohorts (all p ≤0.005), respectively. Responses were maintained or improved at Week 52, after dose escalation in 91% and 80% of the 2 mg and 5 mg cohorts, respectively. At Week 52, composite response (ALP <1.67xULN, ≥15% ALP decrease, and normal total bilirubin) rates were 64%, 53%, and 67%, and ALP normalization rates were 9%, 13%, and 33% in the 2 mg, 5 mg, and 10 mg cohorts, respectively. Pruritus visual analog scale score was decreased in the 5 mg and 10 mg cohorts. There were no treatment-related serious adverse events, and 4 patients discontinued due to adverse events. CONCLUSIONS: Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus. GOV NUMBER: NCT02955602 CLINICALTRIALSREGISTER. EU NUMBER: 2016-002996-91 LAY SUMMARY: Current treatment options for patients living with primary biliary cholangitis (PBC) are not optimal due to inadequate effectiveness or undesirable side effects. Patients with PBC who took seladelpar, a new treatment being developed for PBC, at increasing doses (2, 5, or 10 mg/day) for 1 year had clinically significant, dose-dependent improvements in key liver tests. Treatment appeared safe and was not associated with any worsening in patient self-reported itch scores.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2022.02.033

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 13

  1. Webb, 2015, The immunogenetics of primary biliary cirrhosis: a comprehensive review, J Autoimmun, 64, 42, 10.1016/j.jaut.2015.07.004 · DOI · Paper page
  2. Galoosian, 2020, Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches, J Clin Transl Hepatol, 8, 49
  3. Gulamhusein, 2020, Beyond biochemical responses, use of histologic staging to predict outcomes of patients with primary biliary cholangitis, Clin Gastroenterol Hepatol, 18, 1033, 10.1016/j.cgh.2019.12.008 · DOI
  4. Kuiper, 2009, Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid, Gastroenterology, 136, 1281, 10.1053/j.gastro.2009.01.003 · DOI · Paper page
  5. Murillo Perez, 2020, Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase, Am J Gastroenterol, 115, 1066, 10.14309/ajg.0000000000000557 · DOI · Paper page
  6. Corpechot, 2019, New treatments/targets for primary biliary cholangitis, JHEP Rep, 1, 203, 10.1016/j.jhepr.2019.05.005 · DOI
  7. Vrins, 2009, Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux, J Lipid Res, 50, 2046, 10.1194/jlr.M800579-JLR200 · DOI · Paper page
  8. Odegaard, 2008, Alternative M2 activation of Kupffer cells by PPAR δ ameliorates obesity-induced insulin resistance, Cell Metab, 7, 496, 10.1016/j.cmet.2008.04.003 · DOI · Paper page
  9. Xia, 2012, Liver X receptor β and peroxisome proliferator-activated receptor δ regulate cholesterol transport in murine cholangiocytes, Hepatology, 56, 2288, 10.1002/hep.25919 · DOI · Paper page
  10. Haczeyni, 2017, The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice, Hepatol Commun, 1, 663, 10.1002/hep4.1072 · DOI · Paper page
  11. Corpechot, 2011, Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome, J Hepatol, 55, 1361, 10.1016/j.jhep.2011.02.031 · DOI · Paper page
  12. Dull, 2018, Management of chronic hepatic itch, Dermatol Clin, 36, 293, 10.1016/j.det.2018.02.008 · DOI
  13. Kremer, 2022, Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis, Liver Int, 42, 112, 10.1111/liv.15039 · DOI · Paper page

Cited by

See all 80

Metadata

Authors
Bowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., Thuluvath, P. J., Levy, C., Swain, M. G., Neff, G. W., Sheridan, D. A., Stanca, C. M., Berg, C. P., Goel, A., Shiffman, M. L., Vierling, J. M., Boudes, P., Steinberg, A., Choi, Y.-J., & McWherter, C. A.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-08
Volume
77
Issue
2
Pages
353-364
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4221099883
Cited by
80
References
14
FWCI
9.20
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
CymaBay Therapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/j.jhep.2022.02.033
The paper
Bowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., Thuluvath, P. J., Levy, C., Swain, M. G., Neff, G. W., Sheridan, D. A., Stanca, C. M., Berg, C. P., Goel, A., Shiffman, M. L., . . . McWherter, C. A. (2022). A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2022.02.033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.